trending Market Intelligence /marketintelligence/en/news-insights/trending/tPEjomw-DX1CLO7BhR50wA2 content esgSubNav
In This List

Auris Medical's deafness treatment fails main goal in phase 3 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Auris Medical's deafness treatment fails main goal in phase 3 trial

Auris Medical Holding AG's AM-111 to treat severe to profound sudden deafness did not meet its main goal of significantly improving hearing in a phase 3 trial.

The Healos trial, which was evaluating the safety and efficacy of AM-111, did not meet the primary endpoint of statistically significant improvement in hearing compared to a placebo at day 28.

A post-hoc analysis of the subpopulation with profound acute hearing loss showed a clinically and statistically significant improvement in the AM-111 0.4 mg/mL treatment group.

In addition, the drug was well tolerated and the primary safety endpoint was met.

Auris Medical also decided to terminate a second ongoing clinical trial called Assent, which had a design very similar to the Healos trial. The company said the design of the Assent trial was no longer adequate to test AM-111.